证券日报网讯12月9日晚间，博济医药（300404）发布公告称，公司获得国家知识产权局颁发的发明专 利证书，发明名称为"一种双氯芬酸钠药物制剂及其制备方法和应用"，专利号ZL202510581633.4，授权 公告日2025年12月5日。公司表示，该专利有利于技术创新，完善知识产权保护体系，提升核心竞争 力。 ...

Core Viewpoint - The stock price of Zhaoyan New Drug (06127) has increased significantly, driven by a surge in the price of experimental monkeys, particularly the crab-eating macaque, which has seen a supply shortage and price increase [5]. Group 1: Company Performance - Zhaoyan New Drug's stock price rose by 7.33% to HKD 17.43, with a trading volume of HKD 211 million [5]. - The company is expected to benefit from the rising prices of experimental monkeys due to its acquisition of monkey breeding facilities, which aims to create an integrated industry chain [5]. Group 2: Industry Trends - The price of crab-eating macaques has surpassed HKD 100,000, with reports indicating prices have reached HKD 120,000 to HKD 130,000 due to supply shortages [5]. - Demand for experimental monkeys is projected to be between 51,300 to 62,600 annually from 2025 to 2027, while supply is estimated at 49,000 to 52,400, indicating a potential supply-demand gap [5]. - The resurgence in new drug development is expected to drive up the usage of experimental monkeys, exacerbating the supply constraints in the short term [5].

Group 1 - The core viewpoint of the article highlights a significant increase in the price of experimental monkeys, particularly the crab-eating macaques, which have surpassed 100,000 yuan, with reports indicating prices have risen to 120,000-130,000 yuan due to supply shortages [1] - The trading performance of Zhaoyan New Drug (603127) shows a rise of over 10%, currently at 17.8 HKD with a trading volume of 172 million HKD, indicating positive market sentiment [1] - According to estimates from Founder Securities, the supply of experimental monkeys is projected to be around 49,000-52,400 annually from 2025 to 2027, while demand is expected to be between 51,300-62,600, suggesting a widening supply-demand gap due to increased usage in new drug development [1] Group 2 - The report from招商证券 indicates that Zhaoyan New Drug's acquisition of monkey breeding facilities aims to create an integrated industry chain, positioning the company to benefit from the rising prices of experimental monkeys, which could enhance profit margins [1] - The short-term outlook suggests that the demand for experimental monkeys is driven by a resurgence in new drug research, while improvements in supply are expected to be challenging, potentially leading to a sustained supply-demand imbalance [1]

Core Viewpoint - The stock price of Zhaoyan New Drug (06127) has increased by over 10%, currently trading at 17.8 HKD with a transaction volume of 172 million HKD, driven by a significant rise in the price and demand for experimental monkeys [1] Group 1: Company Insights - Zhaoyan New Drug is expected to benefit from the rising prices of experimental monkeys, as the company has acquired monkey farms to create an integrated industry chain [1] - The company’s stock performance reflects market optimism regarding its future profitability linked to the rising costs of experimental monkeys [1] Group 2: Industry Trends - The price of the crab-eating macaque has surpassed 100,000 RMB, with reports indicating that prices have reached 120,000 to 130,000 RMB due to a supply shortage [1] - Demand for experimental monkeys is projected to be between 51,300 to 62,600 units annually from 2025 to 2027, while supply is estimated at 49,000 to 52,400 units per year, indicating a potential supply-demand gap [1] - The short-term increase in demand for experimental monkeys is driven by a resurgence in new drug development, while supply-side improvements are expected to be challenging [1]

Core Viewpoint - The Weifang Municipal Commission for Discipline Inspection and Supervision is actively addressing issues related to redundant medical examinations and improper charges in the healthcare sector, aiming to alleviate the financial burden on citizens [1][2][3] Group 1: Issues Addressed - The Weifang Municipal Commission has focused on resolving public concerns regarding excessive medical examinations and high treatment costs by implementing a rectification plan in collaboration with health authorities [1] - A comprehensive review of complaints related to redundant medical checks and improper charges has been conducted, resulting in the establishment of a rectification ledger for 78 identified issues [1][3] Group 2: Supervision and Monitoring - The Commission employs various methods, including participation in health committee meetings and on-site inspections, to continuously monitor and address the challenges of redundant medical examinations and improper charges [2] - A new monitoring platform, "E-Lian Tong," has been developed to oversee key areas such as drug procurement and material management, enhancing the ability to detect and warn against irregularities [2] Group 3: Outcomes and Measures - Since the initiation of the rectification efforts, the Commission has identified 31 specific issues related to non-compliant medical practices, leading to the investigation and disciplinary action against five individuals [3] - The healthcare system in Weifang has improved collaboration among various departments, enhancing data analysis and joint assessments to prevent unnecessary redundant medical examinations [3]

2025年12月6日，一场汇聚中外医学智慧、跨越学科边界的学术盛会——"人体复杂系统运行规律及疑难 疾病临床决策研讨会"通过线上方式隆重举行。本次会议由中国生物多样性与绿色发展基金会肿瘤生态 委员会、中国老年保健协会肿瘤支持专业委员会牵头，联合中国慈善总会科技与文化发展委员会、中国 科学院数学与系统科学研究院、北京中西医慢病防治学会、经方与现代中药融合创新全国重点实验室、 肿瘤智库主动健康与疑难杂症临床决策中心、轻又清微生态健康食品研发中心、青岛普罗吉有限公司等 多家权威机构共同主办。会议上，基于创新理论构建的"肿瘤智库复杂疾病决策平台"——肿瘤生态学一 站式诊疗平台上线，标志着针对癌症中晚期、慢性病等复杂疾病的诊疗，开始从传统的"分科对抗"模 式，转向"系统调控、生态重建"的新范式。 会议提出的"人体复杂系统运行规律与疑难复杂疾病临床决策理论体系"认为，人体应被理解为一个具备 多层反馈、高度整合的智能生态系统，通过精密调节维持动态平衡。而疾病，尤其是疑难复杂疾病，是 跨尺度（从基因到环境）、动态演进中的"系统失稳"过程，远非单一器官的故障。 会议认为，必须打破传统以症状和器官为中心的疾病分类束缚，构建融合遗 ...

Core Points - The "Hong Kong-Macao Drug and Medical Device Pass" has designated a total of 71 medical institutions in Guangdong Province as of December 8, 2023 [1][2] - The fourth batch of designated hospitals includes 27 new medical institutions, such as the Southern Medical University Zhujiang Hospital [1] - Since the implementation of the "Hong Kong-Macao Drug and Medical Device Pass" in 2021, a total of 140 varieties of drugs and medical devices have been approved for import, benefiting approximately 17,000 patients [2] Summary by Sections Implementation and Designation - The "Hong Kong-Macao Drug and Medical Device Pass" was officially implemented in Guangdong Province in 2021, with the first three batches of designated medical institutions announced in August 2021, February 2023, and September 2024 [2] - The recent announcement includes 27 new hospitals, bringing the total to 71 designated institutions [1][2] Regulatory and Operational Aspects - The Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration have mandated that designated medical institutions enhance supervision and management, deepen cooperation with Hong Kong and Macao in medical services, and ensure the safety of imported drugs and medical devices [1] - The institutions are required to continuously improve the relevant systems of the "Hong Kong-Macao Drug and Medical Device Pass" [1] Patient Impact - The approved imports include 63 types of drugs and 77 types of medical devices, which have collectively served around 17,000 patients [2]

绿色经济(01315)发布公告，于2025年9月15日至9月17日，集团已于公开市场出售所有投资者股份(公司 全资附属公司加华认购的274.86万股佰泽医疗股份)，总代价约为3020万港元。于出售事项完成后，公 司将不再于佰泽医疗拥有任何投资。 ...

此外，合富中国表示，公司控股股东合富(香港)控股有限公司存在减持计划，截至12月8日，控股股东 尚未减持，公司不存在应披露而未披露的重大事项。 北京商报讯(记者丁宁)12月8日晚间，当日涨停收盘的合富中国（603122）发布公告称，公司股票价格 于12月4日、12月5日及12月8日连续三个交易日内日收盘价格涨幅偏离值累计超过20%，根据上交所的 有关规定，属于股票交易异常波动情形。 合富中国表示，公司股价累计涨幅已严重偏离基本面，投资者参与交易可能面临较大风险。自10月28日 至12月8日，公司股票有十六个交易日以涨停价收盘，并6次触及股价异常波动、3次触及严重异常波动 情形，期间累计涨幅高达336.83%。截至12月8日收盘，公司股价为29.18元/股，处于历史最高位。股价 短期内连续上涨，存在市场情绪过热、非理性炒作风险，已明显高于同期行业及上证指数涨幅，且严重 显著偏离公司基本面，随时存在快速下跌风险。 ...

锦欣生殖(01951)发布公告，于2025年12月8日，该公司斥资1484.91万港元回购592.85万股股份，每股回 购价格为2.47-2.58港元。 ...